Scientific deep-dive

GLP-1s in People Being Treated for Cancer

Lower mortality and fewer hospitalizations than metformin, at a hazard ratio of 0.875. A second comparison against insulin produced a bigger number, and the bigger number is the less trustworthy one.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

People with both diabetes and cancer who took GLP-1 drugs had lower all-cause mortality and fewer hospitalizations than those on metformin, with a hazard ratio of 0.875.[1] A second analysis, comparing people newly started on a GLP-1 against people newly started on insulin, produced a bigger number. The choice of comparator is a reason to be suspicious of it.

What was found

All-cause mortality in patients with diabetes and cancer, by comparison group.
ComparisonHazard ratio
GLP-1 vs metformin (monotherapy setting)0.875 (95% CI 0.778–0.985), p=0.0268
Newly started GLP-1 vs newly started insulin0.786 (95% CI 0.662–0.934), p=0.0062

Secondary analyses found lower rates of all-cause hospitalization, sepsis, major adverse cardiovascular events, pulmonary embolism and pneumonia. Subanalyses stratified by body mass index and HbA1c did not reach statistical significance.[1]

Which number to trust

The metformin comparison is the more believable one, and it is the smaller. Metformin is typically first-line and given to people whose diabetes is relatively well controlled, which makes them a reasonably fair comparison group.

Insulin is not. Being on insulin usually marks longer-standing, harder-to-control diabetes and more complications. Comparing a GLP-1 against insulin measures, in part, how sick each group already was before anyone counted a death.

Against insulin the hazard ratio was 0.786; against metformin, the fairer comparison, it was 0.875.

We covered this at length in the cancer cohorts article, where a study reported 91% lower breast cancer mortality against insulin users and nothing at all against a modern comparator in the same paper. The same bias is at work here, but the effect size is far more modest, which is itself reassuring about this study’s quality. Studying people without diabetes removes that comparator problem, though a cohort that did so followed people for a median of only two years.

The subanalyses that failed

Stratifying by BMI and HbA1c did not reach significance.[1] That matters because it leaves the two most obvious explanations for how the drug might help, weight loss and glycemic control, neither confirmed nor ruled out. If the benefit were driven by either, you would expect it to track them, and these subanalyses could not show whether it does.

It may simply be that those subgroups were too small to show anything. But it means the study cannot tell you why the association exists, only that it does, in a design that cannot establish causation anyway.

What this changes for a patient

  • Nothing on its own. No GLP-1 is indicated for cancer, and the authors call for prospective, well-controlled studies. What else has been published for people after cancer is collected in ten studies on GLP-1s after cancer.
  • It is reassuring about continuation. People with diabetes who develop cancer often wonder whether to stop everything metabolic. This does not suggest harm.
  • The hospitalization and infection findings are relevant to cancer care specifically, where sepsis and pneumonia are major causes of treatment interruption. That is consistent with the infection study, here seen in a much sicker population.
  • It belongs with the oncologist, who is weighing appetite, nutrition and treatment tolerance in a way no general finding addresses.
One caution specific to this population. Appetite suppression is not neutral during cancer treatment, where maintaining weight and nutritional status is often part of the treatment plan rather than a side issue. Fertility-sparing treatment of endometrial cancer is the reverse case, where weight loss is part of the plan and semaglutide has been compared with surgery. Any decision about a GLP-1 during active cancer therapy is a conversation with the team managing that treatment, not a conclusion from a mortality hazard ratio.

Frequently Asked Questions

An observational study of people with both diabetes and cancer found lower all-cause mortality on GLP-1 drugs than on metformin, with a hazard ratio of 0.875, plus fewer hospitalizations, sepsis and cardiovascular events. It cannot establish cause, and the authors call for prospective studies.
Because insulin marks longer-standing, harder-to-control diabetes with more complications. Comparing against insulin users measures partly how sick each group already was. The metformin comparison is fairer and produces the smaller, more believable number.
The study cannot say. Subanalyses stratified by BMI and HbA1c did not reach statistical significance, so those two explanations are neither confirmed nor ruled out; the subgroups may simply have been too small.
That belongs with the oncology team. Appetite suppression is not neutral during cancer treatment, where maintaining weight and nutritional status is often part of the plan. Nothing here suggests harm, and nothing here is a reason to start or continue without that conversation.
Because sepsis and pneumonia are major causes of interrupted cancer treatment. Lower rates of both, in a population this sick, are consistent with a separate and better-designed study of infection risk in diabetes.

References

  1. 1.Mahadevan A, Vosooghi A, Arora JS, et al. GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization The Journal of Clinical Endocrinology and Metabolism. 2026. PMID: 41482652.

GLP-1s and Cancer: What the Cohorts Actually Show

One study found breast cancer mortality 91% lower on GLP-1s than on insulin, and no difference at all against SGLT2 inhibitors. The comparison group produced the result. What is known, and how to read this kind of evidence.

7 min read

Cancer Risk in People Without Diabetes

A study in obese adults without diabetes found 41% lower incidence of obesity-associated cancers. The median follow-up was two years, far too short to establish that a drug prevented anything.

6 min read

GLP-1s and Cancer: The Randomized Answer

Randomized evidence finds little or no effect on obesity-related cancers: pancreatic somewhere between 9 fewer and 6 more per 10,000. The trials were not designed to look for cancer and had short follow-up.

6 min read

The Group That Lost Least Did Best

A study compared surgery, semaglutide and a lifestyle program in young women with endometrial cancer. The group that lost the least weight had the highest tumor remission rate, and that is almost certainly not what it looks like.

6 min read

Are GLP-1s Longevity Drugs? What the Death and Outcome Data Show

GLP-1 drugs lower deaths from any cause by about 12% in people with heart disease, diabetes or kidney disease. No trial has tested them in healthy adults or measured lifespan. SELECT, FLOW, LEADER, dementia, cancer and muscle, in one place.

11 min read

Losing Fast Early: What It Predicts

Rapid responders in SURMOUNT-5, those down 15% or more at week 24, reported more gastrointestinal side effects and completed treatment at a similar rate to everyone else. The likely explanation is that fast loss and nausea reflect the same underlying response.

5 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

ShedRx

Oral orforglipron alongside the injectables

From $149/mo + membership

Get started →
Read full review →
8.1

Sesame Care

Oral orforglipron alongside the injectables

9.1

Collective

Flat any-dose pricing, if you can absorb a $199 annual membership on top

From $59/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →